WUXI BIO completes HK$74.88 million share buyback, lifting pending cancellations to 21.10 million shares

Bulletin Express

Jun 09

On 9 June 2026, WuXi Biologics (Cayman) Inc. reported the on-market repurchase of 2.52 million ordinary shares at prices ranging from HK$28.58 to HK$30.52, for a total consideration of HK$74.88 million.

Including this latest transaction, shares repurchased between 27 May and 9 June 2026 but not yet cancelled now stand at 21.10 million, equivalent to approximately 0.51 % of the company’s 4.14 billion issued shares.

Under the buyback mandate granted on 6 June 2025—authorising the company to repurchase up to 406.87 million shares—WUXI BIO has so far acquired 44.28 million shares, representing 1.09 % of the issued share base at the time the mandate was approved.

The company’s total issued shares remain unchanged at 4.14 billion as of 9 June 2026 because all repurchased shares are pending formal cancellation. A 30-day moratorium restricts any new share issuance or treasury-share sale until 9 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1185470516"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185470516\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185470516?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185470516","market":"hk","top_or_hot":-1,"title":"WUXI BIO completes HK$74.88 million share buyback, lifting pending cancellations to 21.10 million shares","media":"Bulletin Express","content":"<p>On 9 June 2026, WuXi Biologics (Cayman) Inc. reported the on-market repurchase of 2.52 million ordinary shares at prices ranging from HK$28.58 to HK$30.52, for a total consideration of HK$74.88 million.</p>\n<p>Including this latest transaction, shares repurchased between 27 May and 9 June 2026 but not yet cancelled now stand at 21.10 million, equivalent to approximately 0.51 % of the company’s 4.14 billion issued shares.</p>\n<p>Under the buyback mandate granted on 6 June 2025—authorising the company to repurchase up to 406.87 million shares—WUXI BIO has so far acquired 44.28 million shares, representing 1.09 % of the issued share base at the time the mandate was approved.</p>\n<p>The company’s total issued shares remain unchanged at 4.14 billion as of 9 June 2026 because all repurchased shares are pending formal cancellation. A 30-day moratorium restricts any new share issuance or treasury-share sale until 9 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WUXI BIO completes HK$74.88 million share buyback, lifting pending cancellations to 21.10 million shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWUXI BIO completes HK$74.88 million share buyback, lifting pending cancellations to 21.10 million shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-09 22:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 9 June 2026, WuXi Biologics (Cayman) Inc. reported the on-market repurchase of 2.52 million ordinary shares at prices ranging from HK$28.58 to HK$30.52, for a total consideration of HK$74.88 million.</p>\n<p>Including this latest transaction, shares repurchased between 27 May and 9 June 2026 but not yet cancelled now stand at 21.10 million, equivalent to approximately 0.51 % of the company’s 4.14 billion issued shares.</p>\n<p>Under the buyback mandate granted on 6 June 2025—authorising the company to repurchase up to 406.87 million shares—WUXI BIO has so far acquired 44.28 million shares, representing 1.09 % of the issued share base at the time the mandate was approved.</p>\n<p>The company’s total issued shares remain unchanged at 4.14 billion as of 9 June 2026 because all repurchased shares are pending formal cancellation. A 30-day moratorium restricts any new share issuance or treasury-share sale until 9 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1185470516","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185470516","pubTimestamp":1781013779,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 9 June 2026, WuXi Biologics (Cayman) Inc. reported the on-market repurchase of 2.52 million ordinary shares at prices ranging from HK$28.58 to HK$30.52, for a total consideration of HK$74.88...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"药明生物完成7488万港元股份回购待注销股份增至2110万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"On 9 June 2026, WuXi Biologics (Cayman) Inc. reported the on-market repurchase of 2.52 million ordinary shares at prices ranging from HK$28.58 to HK$30.52, for a total consideration of HK$74.88 million.\nIncluding this latest transaction, shares repurchased between 27 May and 9 June 2026 but not yet cancelled now stand at 21.10 million, equivalent to approximately 0.51 % of the company’s 4.14 billion issued shares.\nUnder the buyback mandate granted on 6 June 2025—authorising the company to repurchase up to 406.87 million shares—WUXI BIO has so far acquired 44.28 million shares, representing 1.09 % of the issued share base at the time the mandate was approved.\nThe company’s total issued shares remain unchanged at 4.14 billion as of 9 June 2026 because all repurchased shares are pending formal cancellation. A 30-day moratorium restricts any new share issuance or treasury-share sale until 9 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}